Experimental drug NU-9—a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS)—improves neuron health in animal models of Alzheimer’s disease, according to a new Northwestern University study.
Leave A Comment